文献速递主动脉疾病

女性患者使用t-Branch即用型支架的早期与中期结局

Early and Mid-Term Outcomes of Females Treated with t-Branch off the Shelf Device.
PubMed 文献 · Ann Vasc Surg · 2023-06-01

这项两中心回顾性观察研究纳入2018年1月1日至2020年9月30日期间153例择期或紧急使用t-Branch支架治疗胸腹主动脉瘤和肾旁动脉瘤的女性患者,其中81例(52.9%)为紧急治疗。结果显示技术成功率97.4%,早期死亡率为16.3%,脊髓缺血和急性肾损伤发生率分别为13.7%和18.3%,择期与紧急治疗组的30天死亡率和脊髓缺血率相似。

要点

  • 153例女性患者中81例(52.9%)为紧急治疗,技术成功率97.4%。
  • 早期死亡率为16.3%(紧急组22% vs 择期组12%,P=0.2),脊髓缺血发生率为13.7%(紧急组11% vs 择期组16%,P=0.2)。
  • 多因素回归分析显示双联抗血小板治疗和β受体阻滞剂与较低的30天死亡率相关,双联抗血小板治疗对脊髓缺血也有预防作用。

核心结论

  • 择期和紧急使用t-Branch支架治疗胸腹主动脉瘤和肾旁动脉瘤的女性患者,其30天死亡率和脊髓缺血率相似。

研究设计与样本

  • 两中心回顾性观察研究,纳入2018年1月1日至2020年9月30日期间择期和紧急使用t-Branch支架(Cook Medical,Bjaeverskov,丹麦)治疗胸腹主动脉瘤和肾旁动脉瘤的女性患者153例,其中81例(52.9%)为紧急治疗。

主要发现

  • 紧急组患者年龄更大(73.2 ± 8.6岁 vs 择期组68.5 ± 6.8岁,P < 0.001),既往冠状动脉球囊扩张/支架置入率更高(16.0% vs 5.6%,P = 0.005),双联抗血小板治疗率更低(46.3% vs 53.7%,P = 0.04)。
  • 技术成功率为97.4%,早期死亡率为16.3%(紧急组22% vs 择期组12%,P = 0.2),脊髓缺血发生率为13.7%(紧急组11% vs 择期组16%,P = 0.2),急性肾损伤发生率为18.3%(紧急组22.2% vs 择期组13.9%,P = 0.18)。
  • 多因素回归分析显示双联抗血小板治疗和β受体阻滞剂与较低的30天死亡率相关,双联抗血小板治疗对脊髓缺血也有预防作用。
  • 紧急组12个月生存率为68.4%(标准误0.07),择期组24个月生存率为75.6%(标准误0.09),P = 0.14;紧急组6个月和18个月免于再干预率分别为81.4%(标准误0.06)和64.7%(标准误0.09),择期组分别为81.7%(标准误0.06)和75.4%(标准误0.081),P = 0.94。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Female sex has been characterized as a risk factor of increased mortality in patients managed for complex aortic aneurysm using endovascular means. This study aimed to present the perioperative and follow-up outcomes of females managed electively or urgently with the t-Branch device and investigate factors affecting the early outcomes. METHODS: A 2-center retrospective observational study was conducted including elective and urgent female patients managed with the t-Branch device (Cook Medical, Bjaeverskov, Denmark) for thoracoabdominal and pararenal aneurysms between January 1, 2018 and September 30, 2020. Primary early outcomes included technical success and 30-day mortality and morbidity [spinal cord ischemia (SCI) and acute kidney injury]. Follow-up survival and freedom from reintervention rates were assessed using Kaplan-Meier estimates. RESULTS: In total, 153 females were included; 81 (52.9%) treated urgently. Urgent patients were older (73.2 ± 8.6 vs. 68.5 ± 6.8 years; P < 0.001) and presented higher previous coronary angioplasty/stenting (16.0% vs. 5.6%, P = 0.005) and lower double antiplatelet therapy (DAPT, 46.3% vs. 53.7%, P = 0.04) rates. Technical success was 97.4%. Early mortality was 16.3% (22% in urgent; 12% in elective; P = 0.2) and SCI and acute kidney injury were diagnosed in 13.7% (11% in urgent; 16% in elective; P = 0.2) and 18.3% (22.2% in urgent; 13.9% in elective; P = 0.18), respectively. Multivariate regression analyses showed that DAPT and b-blockers were related to lower 30-day mortality. DAPT was also preventive for SCI. Survival rates were 68.4% [standard error (SE) 0.07] at 12 months for the urgent and 75.6% (SE 0.09) at 24 months for the elective group (P = 0.14). Freedom from reintervention rates were 81.4% (SE 0.06) at 6 months and 64.7% (SE 0.09) at 18 months for the urgent and 81.7% (SE 0.06) at 6 months and 75.4% (SE 0.081) at 18 months for the elective group (P = 0.94). CONCLUSIONS: Female patients managed with the t-Branch device for thoracoabdominal and pararenal aneurysms in elective and urgent setting presented similar 30-day mortality and SCI rates.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Nana P, Spanos K, Kölbel T, et al. Early and Mid-Term Outcomes of Females Treated with t-Branch off the Shelf Device. Ann Vasc Surg. 2023. PMID: 37268105. doi:10.1016/j.avsg.2023.05.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。